ABL Bio to Hold Overseas NDR in Hong Kong and Singapore

Enhancing Shareholder Value Through Ongoing Global NDRs

ABL Bio, a company specializing in bispecific antibodies, announced on January 23 that it will hold overseas non-deal roadshows (NDR) in Hong Kong and Singapore from February 2 to 4 (local time).

ABL Bio logo image. ABL Bio

This NDR is organized to share ABL Bio's bispecific antibody platform, the current status of its major pipelines, and its mid- to long-term business strategies with overseas institutional investors. The company aims to expand its global investor network and enhance shareholder value by attracting foreign capital.

ABL Bio is expanding its pipeline with a focus on the BBB shuttle platform 'Grabody-B' and the 4-1BB-based immuno-oncology platform 'Grabody-T.' Grabody-B, a technology targeting IGF1R, has been licensed out to GSK and Eli Lilly. The Parkinson's disease treatment ABL301 was licensed to Sanofi and has completed Phase 1 clinical trials in the United States.

Among the Grabody-T-based pipeline candidates-ABL111, ABL503, and ABL103-ABL111 demonstrated significant efficacy and safety in a Phase 1b clinical trial for gastric cancer patients in combination with nivolumab and a chemotherapeutic agent.

ABL Bio's first bispecific antibody, ABL001, is currently undergoing global Phase 2/3 clinical trials as a second-line treatment for cholangiocarcinoma by Compass Therapeutics. The company plans to release key clinical indicators, including progression-free survival and overall survival, in the first half of this year.

Lee Sanghoon, CEO of ABL Bio, stated, "Following our NDR in the United States, we will continue to engage with overseas investors in Hong Kong and Singapore," adding, "Through ongoing global NDRs, we aim to enhance both our corporate value and shareholder value."